{"schema_version":"secwatch.filing_event.v1","accession":"0001689548-26-000031","form_type":"8-K","ticker":"PRAX","cik":"0001689548","company_name":"Praxis Precision Medicines, Inc.","filed_at":"2026-04-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.737860+00:00","generated_at":"2026-05-15T07:22:46.570747+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Praxis reports positive EMBRAVE Part A data for elsunersen; FDA grants priority review for relutrigine","bullets":["Elsunersen achieved 77% placebo-adjusted seizure reduction (p=0.015) in 9-patient Phase 1/2 trial.","57% of elsunersen patients had ≥28-day seizure freedom; improvements in sleep, motor function, attention.","Relutrigine NDA accepted for priority review by FDA with PDUFA target date of September 27, 2026.","Elsunersen well tolerated; no drug-related SAEs, no discontinuations, no neuroinflammation at doses up to 8 mg.","All 9 patients continued into open-label extension; efficacy sustained for up to one year."],"urls":{"canonical":"https://secwatch.observer/filing/0001689548-26-000031","json":"https://secwatch.observer/filing/0001689548-26-000031.json","markdown":"https://secwatch.observer/filing/0001689548-26-000031.md","text":"https://secwatch.observer/filing/0001689548-26-000031.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1689548/000168954826000031/0001689548-26-000031-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1689548/000168954826000031/prax-20260406.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T07:22:46.570747+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}